058820 — CMG Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapSucker Stock

Annual income statement for CMG Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	58,623	64,460	69,475	82,197	93,907
Cost of Revenue
Gross Profit	28,923	31,210	33,451	40,901	43,703
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	56,110	63,906	66,275	79,545	86,804
Operating Profit	2,513	554	3,200	2,652	7,103
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,837	569	3,549	-1,255	6,731
Provision for Income Taxes
Net Income After Taxes	3,051	215	3,165	-388	6,455
Net Income Before Extraordinary Items
Net Income	3,051	215	3,165	-388	6,455
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	3,051	215	3,165	-388	6,983
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	25.7	7.48	12.9	-1.15	21.4
Dividends per Share